Parallel Advisors, LLC Fibrogen Inc Transaction History

Parallel Advisors, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 May 20, 2024	SELL	$2.49 - $20.59 $22 - $185	-9 Reduced 30.0%	21 $0
Q2 2023 Aug 04, 2023	SELL	$2.49 - $20.59 $22 - $185	-9 Reduced 30.0%	21 $0
Q1 2023 May 20, 2024	BUY	$15.95 - $25.18 $478 - $755	30 New	30 $0
Q4 2022 Feb 03, 2023	SELL	$13.27 - $17.73 $199 - $265	-15 Reduced 33.33%	30 $0
Q3 2022 Nov 10, 2022	BUY	$11.4 - $14.6 $239 - $306	21 Added 87.5%	45 $1,000
Q2 2022 Aug 01, 2022	BUY	$7.94 - $12.96 $190 - $311	24 New	24 $0
Q1 2022 Apr 28, 2022	SELL	$12.02 - $16.79 $6,430 - $8,982	-535 Closed	0 $0
Q4 2021 Jan 20, 2022	BUY	$9.93 - $15.39 $5,312 - $8,233	535 New	535 $8,000
Q2 2021 Aug 06, 2021	SELL	$18.57 - $35.68 $649 - $1,248	-35 Closed	0 $0
Q2 2020 Jul 16, 2020	BUY	$32.57 - $42.83 $32 - $42	1 Added 2.94%	35 $1,000
Q1 2020 Apr 27, 2020	SELL	$23.3 - $45.96 $978 - $1,930	-42 Reduced 55.26%	34 $1,000
Q2 2019 Aug 05, 2019	BUY	$35.13 - $55.53 $2,669 - $4,220	76 New	76 $3,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.